8/468145

```
Trying 3106016892...Open

Welcome to STN International!  Enter x:x
LOGINID:ssspta1813nxm
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * *
* *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Dec 17   The CA Lexicon available in the CAPLUS and CA files
 NEWS  3  Feb 06   Engineering Information Encompass files have new
names
 NEWS  4  Feb 16   TOXLINE no longer being updated
 NEWS  5  Apr 23   Search Derwent WPINDEX by chemical structure
 NEWS  6  Apr 23   PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
 NEWS  7  May 07   DGENE Reload
 NEWS  8  Jun 20   Published patent applications (A1) are now in
USPATFULL
 NEWS  9  JUL 13   New SDI alert frequency now available in Derwent's
                   DWPI and DPCI
 NEWS 10  Aug 23   In-process records and more frequent updates now in
                   MEDLINE
 NEWS 11  Aug 23   PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
 NEWS 12  Aug 23   Adis Newsletters (ADISNEWS) now available on STN
 NEWS 13  Sep 17   IMSworld Pharmaceutical Company Directory name
change
                   to PHARMASEARCH
 NEWS 14  Oct 09   Korean abstracts now included in Derwent World
Patents
                   Index
 NEWS 15  Oct 09   Number of Derwent World Patents Index updates
increased
 NEWS 16  Oct 15   Calculated properties now in the REGISTRY/ZREGISTRY
File
 NEWS 17  Oct 22   Over 1 million reactions added to CASREACT
 NEWS 18  Oct 22   DGENE GETSIM has been improved
 NEWS 19  Oct 29   AAASD no longer available

 NEWS EXPRESS  August 15 CURRENT WINDOWS VERSION IS V6.0c,
               CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP),
               AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.
```

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:53:06 ON 07 NOV 2001

=> file embase medline biosis uspatfull japio wpids caplus agricola lifesci biotechds jicst-eplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'EMBASE' ENTERED AT 15:53:14 ON 07 NOV 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 15:53:14 ON 07 NOV 2001

FILE 'BIOSIS' ENTERED AT 15:53:14 ON 07 NOV 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 15:53:14 ON 07 NOV 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 15:53:14 ON 07 NOV 2001
COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

FILE 'WPIDS' ENTERED AT 15:53:14 ON 07 NOV 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'CAPLUS' ENTERED AT 15:53:14 ON 07 NOV 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'AGRICOLA' ENTERED AT 15:53:14 ON 07 NOV 2001

FILE 'LIFESCI' ENTERED AT 15:53:14 ON 07 NOV 2001
COPYRIGHT (C) 2001 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHDS' ENTERED AT 15:53:14 ON 07 NOV 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'JICST-EPLUS' ENTERED AT 15:53:14 ON 07 NOV 2001
COPYRIGHT (C) 2001 Japan Science and Technology Corporation (JST)

=> e engel jurgen/au

E1	1	ENGEL JULIE S/AU
E2	2	ENGEL JUNE/AU

```
E3          222 --> ENGEL JURGEN/AU
E4            1     ENGEL JURGN/AU
E5           19     ENGEL JUTTA/AU
E6          449     ENGEL K/AU
E7           11     ENGEL K A/AU
E8           21     ENGEL K C/AU
E9            6     ENGEL K E/AU
E10           2     ENGEL K G/AU
E11         113     ENGEL K H/AU
E12           8     ENGEL K J/AU

=> s e3

L1          222 "ENGEL JURGEN"/AU

=> e wichert burkhard/au

E1            1     WICHERT BOB/AU
E2            1     WICHERT BODO/AU
E3           11 --> WICHERT BURKHARD/AU
E4            1     WICHERT BURKHARD V/AU
E5            5     WICHERT C/AU
E6            9     WICHERT D/AU
E7            1     WICHERT D M/AU
E8            6     WICHERT E/AU
E9            2     WICHERT E V O N/AU
E10           8     WICHERT EDWARD/AU
E11           5     WICHERT F/AU
E12           2     WICHERT FRIEDEL/AU

=> s e3-e4

L2           12 ("WICHERT BURKHARD"/AU OR "WICHERT BURKHARD V"/AU)

=> e sauerbier dieter/au

E1           14     SAUERBIER D/AU
E2            1     SAUERBIER DIESTER/AU
E3           27 --> SAUERBIER DIETER/AU
E4            1     SAUERBIER E/AU
E5            1     SAUERBIER F/AU
E6            3     SAUERBIER G A/AU
E7           18     SAUERBIER H/AU
E8            4     SAUERBIER HEINZ/AU
E9            1     SAUERBIER HERBERT/AU
E10          74     SAUERBIER I/AU
E11          15     SAUERBIER INGRID/AU
E12          12     SAUERBIER J/AU

=> s e1-e3

L3           42 ("SAUERBIER D"/AU OR "SAUERBIER DIESTER"/AU OR
"SAUERBIER DIETER
               "/AU)

=> e reissman thomas/au

E1            1     REISSMAN T L/AU
E2            1     REISSMAN TH/AU
```

```
E3            2 --> REISSMAN THOMAS/AU
E4            1     REISSMAN THOMAS LINCOLN/AU
E5            2     REISSMAN Z/AU
E6            2     REISSMANN A/AU
E7            9     REISSMANN B/AU
E8            1     REISSMANN C/AU
E9            8     REISSMANN C B/AU
E10          12     REISSMANN CARLOS BRUNO/AU
E11          23     REISSMANN E/AU
E12           4     REISSMANN EVA/AU

=> s e1-e4

L4            5 ("REISSMAN T L"/AU OR "REISSMAN TH"/AU OR "REISSMAN
THOMAS"/AU
                OR "REISSMAN THOMAS LINCOLN"/AU)

=> s l1-l4

L5          261 (L1 OR L2 OR L3 OR L4)

=> s l5 and cetrorelix

L6           29 L5 AND CETRORELIX

=> dup rem l6

PROCESSING COMPLETED FOR L6
L7            22 DUP REM L6 (7 DUPLICATES REMOVED)

=> d bib ab 1-22


L7   ANSWER 1 OF 22  USPATFULL
AN     2001:173567  USPATFULL
TI     Means for treating prostate hypertrophy and prostate cancer
IN     Engel, Jurgen, Alzenau, Germany, Federal Republic of
       Reissmann, Thomas, Frankfurt am Main, Germany, Federal
Republic of
       Riethmuller-Winzen, Hilde, Frankfurt am Main, Germany, Federal
Republic
       of
       Rawert, Jurgen, Alzenau, Germany, Federal Republic of
PA     ASTA Medica Aktiengesellschaft, Dresden, Germany, Federal
Republic of
       (non-U.S. corporation)
PI     US 6300313          B1   20011009
AI     US 1999-401851           19990922 (9)
RLI    Division of Ser. No. US 1998-57458, filed on 9 Apr 1998, now
patented,
       Pat. No. US 5998377
PRAI   US 1996-25990       19960912 (60)
       US 1997-43228       19970410 (60)
DT     Utility
FS     GRANTED
EXNAM  Primary Examiner: Goldberg, Jerome D.
LREP   Pillsbury Winthrop LLP
CLMN   Number of Claims: 5
ECL    Exemplary Claim: 1
```

DRWN 7 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 258
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs **Cetrorelix** alone or in combination with .alpha.-reductase inhibitors or .alpha.-receptor blocking agents. The regiment reduces the volume of the prostate and avoids the side effects associated with testosterone levels being in a castration range. **Cetrorelix** is administered at dosages between 0.5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per day to 0.30 mg/kg body weight per week or at levels of about 25 to 120 mg of **Cetrorelix** per month or 0.376 mg/kg to 1.71 mg/kg per month. **Cetrorelix** can be administered with .alpha.-reductase inhibitors or a .alpha.-receptor blocking agents.

L7 ANSWER 2 OF 22 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 1
AN 2001:192045 BIOSIS
DN PREV200100192045
TI Diagnostic composition containing an LH-RH antagonist for hysteroscopy.
AU **Engel, Jurgen (1)**; Diedrich, Klaus; Felberbaum, Ricardo
CS (1) Alzenau Germany
ASSIGNEE: Asta Medica Aktiengesellschaft, Germany
PI US 6106805 August 22, 2000
SO Official Gazette of the United States Patent and Trademark Office Patents,
(Aug. 22, 2000) Vol. 1237, No. 4, pp. No Pagination. e-file.
ISSN: 0098-1133.
DT Patent
LA English
AB The invention relates to a diagnostic composition for improving the effectiveness of hysteroscopy, characterized in that it contains an LH-RH antagonist, in particular **cetrorelix**. The composition is envisaged for use prior to hysteroscopy and/or for preparation for surgery, specifically in a single dose of between 0.1 and 2 mg/kg. However, the composition can also be administered, for use prior to hysteroscopy and/or for preparation for surgery, in a multiple dose of between 0.01 and 0.5 mg/kg, preferably spread over 1-14 days. The composition is furthermore suitable for use in hysteroscopy in combination with the subsequent treatment of pathological conditions of the uterus such as myoma and endometrial hyperplasia.

L7 ANSWER 3 OF 22 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 2
AN 2000:477618 BIOSIS
DN PREV200000477618

TI Process for the preparation of immobilized and activity-stabilized
complexes of LHRH antagonists.
AU **Engel, Jurgen (1)**; Deger, Wolfgang; Reissmann, Thomas; Losse, Gunter; Naumann, Wolfgang; Murgas, Sandra
CS (1) Alzenau Germany
ASSIGNEE: Asta Medica Aktiengesellschaft, Dresden, Germany
PI US 6054555 April 25, 2000
SO Official Gazette of the United States Patent and Trademark Office Patents,
(Apr. 25, 2000) Vol. 1233, No. 4, pp. No pagination. e-file.
ISSN: 0098-1133.
DT Patent
LA English
AB In this invention, a release-delaying system is to be developed for LHRH
antagonists, in particular for **cetrorelix**, which allows the active compound to be released in a controlled manner over several weeks
by complexation with suitable biophilic carriers. The acidic polyamino
acids polyglutamic acid and polyaspartic acid were selected for complexation with **cetrorelix**. The **cetrorelix** polyamino acid complexes are prepared from aqueous solutions by combination of the
solutions and precipitation of the complexes, which are subsequently
centrifuged off and dried over P2 O5 in vacuo. If complexes having a
defined composition are to be obtained, lyophilization proves to be a
suitable method. The **cetrorelix**-carboxylic acid complexes were also prepared from the aqueous solutions. In the random liberation system,
the acidic polyamino acids poly-Glu and poly-Asp showed good release-delaying properties as a function of the hydrophobicity and the
molecular mass of the polyamino acid. In animal experiments, it was
possible to confirm the activity of the **cetrorelix**-polyamino acid complexes as a depot system in principle. It is thus possible by
complexation of **cetrorelix** with polyamino acids to achieve testosterone suppression in male rats over 600 hours. The release of
active compound here can be controlled by the nature and the molecular
mass of the polymers.

L7 ANSWER 4 OF 22 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 3
AN 2000:484741 BIOSIS
DN PREV200000484741
TI Means for treating prostate hypertrophy and prostate cancer.
AU **Engel, Jurgen (1)**; Reissmann, Thomas; Riethmuller-Winzen, Hilde; Rawert, Jurgen
CS (1) Alzenau Germany
ASSIGNEE: Asta Medica Aktiengesellschaft, Germany
PI US 6054432 April 25, 2000
SO Official Gazette of the United States Patent and Trademark Office Patents,

(Apr. 25, 2000) Vol. 1233, No. 4, pp. No pagination. e-file.
ISSN: 0098-1133.
DT Patent
LA English
AB A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs **Cetrorelix** alone or in combination with alpha-reductase inhibitors or alpha-receptor blocking agents. The regimen reduces the volume of the prostate and avoids the side effects associated with testosterone levels being in a castration range **Cetrorelix** is administered at dosages between 0,5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per day to 0,30 mg/kg body weight per week or at levels of about 25 to 120 mg of **Cetrorelix** per month or 0.376 mg kg to 1.71 mg/kg per month **Cetrorelix** can be administered with alpha-reductase inhibitors or alpha-receptor blocking agents.

L7 ANSWER 5 OF 22 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 4
AN 2000:355483 BIOSIS
DN PREV200000355483
TI Immobilized and activity-stabilized complexes of LHRH antagonists and processes for their preparation.
AU **Engel, Jurgen (1)**; Deger, Wolfgang; Reissmann, Thomas; Losse, Gunter; Naumann, Wolfgang; Murgas, Sandr
CS (1) Alzenau Germany
ASSIGNEE: Asta Medica Aktiengesellschaft, Dresden, Germany
PI US 6022860 February 08, 2000
SO Official Gazette of the United States Patent and Trademark Office Patents,
(Feb. 8, 2000) Vol. 1231, No. 2, pp. No pagination. e-file.
ISSN: 0098-1133.
DT Patent
LA English
AB In this invention, a release-delaying system is to be developed for LHRH antagonists, in particular for **cetrorelix**, which allows the active compound to be released in a controlled manner over several weeks by complexation with suitable biophilic carriers. The acidic polyamino acids polyglutamic acid and polyaspartic acid were selected for complexation with **cetrorelix**. The **cetrorelix** polyamino acid complexes are prepared from aqueous solutions by combination of the solutions and precipitation of the complexes, which are subsequently centrifuged off and dried over P2 O5 in vacuo. If complexes having a defined composition are to be obtained, lyophilization proves to be a suitable method. The **cetrorelix**-carboxylic acid complexes were also prepared from the aqueous solutions. In the random liberation system, the acidic polyamino acids poly-Glu and poly-Asp showed good release-delaying properties as a function of the hydrophobicity and the

molecular mass of the polyamino acid. In animal experiments, it was possible to confirm the activity of the **cetrorelix**-polyamino acid complexes as a depot system in principle. It is thus possible by complexation of **cetrorelix** with polyamino acids to achieve testosterone suppression in male rats over 600 hours. The release of active compound here can be controlled by the nature and the molecular mass of the polymers.

L7 ANSWER 6 OF 22 USPATFULL
AN 2000:70812 USPATFULL
TI Means for treating prostate hypertrophy and prostate cancer
IN **Engel, Jurgen**, Alzenau, Germany, Federal Republic of
Reissmann, Thomas, Frankfurt am Main, Germany, Federal Republic of
Riethmuller-Winzen, Hilde, Frankfurt am Main, Germany, Federal Republic of
Rawert, Jurgen, Alzenau, Germany, Federal Republic of
PA ASTA Medica AG, Dresden, Germany, Federal Republic of (non-U.S. corporation)
PI US 6071882 20000606
AI US 1998-62704 19980420 (9)
RLI Division of Ser. No. US 1997-908198, filed on 7 Aug 1997
PRAI US 1996-25990 19960912 (60)
US 1997-43228 19970410 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Goldberg, Jerome D.
LREP Pillsbury Madison & Sutro LLP
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 273
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs **Cetrorelix** alone or in combination with .alpha.-reductase inhibitors or .alpha.-receptor blocking agents. The regimen reduces the volume of the prostate and avoids the side effects associated with testosterone levels being in a castration range. **Cetrorelix** is administered at dosages between 0.5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per day to 0.30 mg/kg body weight per week or at levels of about 25 to 120 mg of **Cetrorelix** per month or 0.376 mg/kg to 1.71 mg/kg per month. **Cetrorelix** can be administered with .alpha.-reductase inhibitors or .alpha.-receptor blocking agents.

L7 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2001 ACS
AN 2000:725497 CAPLUS
DN 133:261948

TI Method for a programmed controlled ovarian stimulation protocol
IN **Engel, Jurgen**; Riethmuller-winzen, Hilde
PA Asta Medica A.-G., Germany
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000059542	A1	20001012	WO 2000-EP2466	20000321

W: AU, BG, BR, BY, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRAI US 1999-127241 P 19990331
US 1999-131632 P 19990428

AB A method of therapeutic management of infertility by programming of controlled ovarian stimulation (COS) and assisted reproductive procedures (ART) the improvement consisting of (a) suppression of premature ovulation with an LHRH-antagonist in controlled ovarian stimulation (COS) and assisted reproductive techniques (ART) with multiple follicle and oocyte development; (b) programming the start of controlled ovarian stimulation (COS) by the administration of progestogen only - or alternatively combined oral contraceptive prepns.; (c) exogenous stimulation of the ovarian follicle growth; (d) ovulation induction with HCG, native LHRH, LHRH-agonists or recombinant LH; (e) application of assisted reprodn. techniques, esp. of IVF, ICSI, GIFT, ZIFT or by intrauterine insemination by sperm injection.

RE.CNT 6
RE
(1) Albano, C; HUMAN REPRODUCTION 1996, V11/10(2114-2118)
(2) Asta Medica Ag; EP 0788799 A 1997 CAPLUS
(3) Asta Medica Ag; CA 2200541 A 1998 CAPLUS
(4) Bouchard, P; OVULATION INDUCTION: UPDATE: THE PROCEEDINGS OF THE WORLDCONGRESS ON OVULATION INDUCTION 1998, P115 CAPLUS
(5) Felberbaum, R; IN VITRO FERT ASSISTED REPROD, PROC WORLD CONGR 1997, P397 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2001 ACS
AN 2000:894792 CAPLUS
DN 134:141823

TI New LHRH antagonists with enhanced biological activity: Preclinical and clinical results
AU Kutscher, Bernhard; Bernd, Michael; Gunther, Eckhard; Deger, Wolfgang; Reissmann, Thomas; Beckers, Thomas; Deghenghi, Romano; **Engel, Jurgen**
CS Corporate Research, ASTA Medica AG, Frankfurt, D-60314, Germany
SO Pept. New Millennium, Proc. Am. Pept. Symp., 16th (2000), Meeting Date 1999, 655-657. Editor(s): Fields, Gregg B.; Tam, James P.; Barany, George. Publisher: Kluwer Academic Publishers, Dordrecht, Neth. CODEN: 69ATHX
DT Conference; General Review
LA English
AB A brief review/discussion with 4 refs. on the title topic with focus on **Cetrorelix**, Antarelix, and D-26344 and their use in treating sex hormone-dependent tumors and nonmalignant conditions.
RE.CNT 4
RE
(1) Bernd, M; PCT/DE96/02171
(2) Deghenghi, R; WO 92/19651 A1 CAPLUS
(3) Kutscher, B; Angew Chem 1997, V109, P2240
(4) Muller, A; Int J Peptide Protein Res 1994, V43, P264 MEDLINE

L7 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2001 ACS
AN 2000:26845 CAPLUS
DN 132:160805
TI Disposition and metabolism of **cetrorelix**, a potent luteinizing hormone-releasing hormone antagonist, in rats and dogs
AU Schwahn, Martin; Schupke, Hubert; Gasparic, Antje; Krone, Dorothee; Peter, Gernot; Hempel, Roland; Kronbach, Thomas; Locher, Mathias; Jahn, Wolfgang; **Engel, Jurgen**
CS Corporate Research and Development, ASTA Medica AG, Frankfurt/Main, D-60314, Germany
SO Drug Metab. Dispos. (2000), 28(1), 10-20
CODEN: DMDSAI; ISSN: 0090-9556
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
AB Disposition and metab. of **cetrorelix** was studied in intact and bile duct-cannulated rats and dogs after s.c. injection. An s.c. dose of 0.1 mg/kg [14C]**cetrorelix** was rapidly and completely absorbed in rats. Tmax in plasma and most tissues was at 2 h. Radioactivity at the injection site in rats declined to 10% by 24 h. The extent of 14C absorption in rats calcd. from excretion until 264 h was 94%. Exposure of the target organ pituitary gland was demonstrated with a time course similar to plasma but on a higher level. Rats excreted 69.6% of radioactivity via feces and 24.3% into urine. Excretion was nearly

complete within 48 h. No enteral resorption was detected. In dogs tmax
in plasma was 1.3 h. 14C- and **cetrorelix** plasma levels were similar until 24 h, indicating a negligible amt. of metabolites. A dose
of 1 mg/kg in dogs showed an increasing influence of a slow absorption
phase (flip-flop). In dogs equal amts. of the 14C dose were found within
192 h in feces and urine, 46 and 48%, resp. In urine of both species,
only intact **cetrorelix** was detected. In bile and feces of both species qual. the same metabolites were found, characterized as truncated
peptides of the parent decapeptide. The major metabolite occurring in
bile of both species was the (1-7)heptapeptide. The amts. of the (1-4)tetrapeptide in feces of rats but not in that of dogs increase with
time, suggesting addnl. degrdn. of the peptide in the gastrointestinal
tract of rats by enteric metabolization.
RE.CNT 24
RE
(2) Bajusz, S; Proc Natl Acad Sci USA 1988, V85, P1637 CAPLUS
(5) Berger, H; Drug Metab Dispos 1993, V21, P818 CAPLUS
(6) Berger, H; Regul Pept 1991, V33, P299 CAPLUS
(7) Chan, R; Biochem Biophys Res Commun 1985, V127, P673 CAPLUS
(8) Chan, R; Drug Metab Dispos 1991, V19, P858 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 22 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 5
AN 2000:292181 BIOSIS
DN PREV200000292181
TI Means for treating prostate cancer.
AU **Engel, Jurgen**; Reissmann, Thomas (1); Riethmuller-Winzen, Hilde; Rawert, Jurgen
CS (1) Frankfurt/Main Germany
ASSIGNEE: ASTA Medica Aktiengesellschaft
PI US 5998377 December 07, 1999
SO Official Gazette of the United States Patent and Trademark Office Patents,
(Dec. 7, 1999) Vol. 1229, No. 1, pp. No pagination. e-file..
ISSN: 0098-1133.
DT Patent
LA English
AB A regime for therapeutic management of a benign prostatic hyperplasia and
prostatic cancer employs **Cetrorelix** alone or in combination with alpha-reductase inhibitors or alpha-receptor blocking agents. The regimen
reduces the volume of the prostate and avoids the side effects associated
with testosterone levels being in a castration range. **Cetrorelix**
is administered at dosages between 0,5 mg/day and 20 mg/week or about
0.014 mg/kg body weight per day to 0,30 mg/kg body weight per week or at
levels of about 25 to 120 mg of **Cetrorelix** per month or 0.376

mg/kg to 1.71 mg/kg per month. **Cetrorelix** can be administered with alpha-reductase inhibitors or alpha-receptor blocking agents.

L7 ANSWER 11 OF 22 USPATFULL
AN 1999:146533 USPATFULL
TI Nova- and decapeptides in the preparation of a drug for the treatment of aids
IN **Engel, Jurgen**, Alzenau, Germany, Federal Republic of
Kutscher, Bernhard, Maintal, Germany, Federal Republic of
Bernd, Michael, Frankfurt am Main, Germany, Federal Republic of
Niemeyer, Ulf, Offenbach, Germany, Federal Republic of
PA ASTA Medica AG, Germany, Federal Republic of (non-U.S. corporation)
PI US 5985834 19991116
WO 9500168 19950105
AI US 1995-569111 19951218 (8)
WO 1994-EP1037 19940402
19951218 PCT 371 date
19951218 PCT 102(e) date
PRAI DE 1993-4320201 19930618
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilla J.; Assistant Examiner: Delacroix-Muirheid, C.
LREP Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Described are LHRH-antagonistic and bombesin-antagonistic nona- and decapeptides suitable for use in the preparation of a drug for the treatment of AIDS and ARC as well as for use in the preparation of an immunostimulation drug.

L7 ANSWER 12 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1999-542841 [46] WPIDS
CR 1994-265229 [33]
DNC C1999-158621
TI Treatment of female infertility, especially by in-vitro fertilization.
DC B04
IN ENGEL, J; REISSMANN, T; **SAUERBIER, D**; WICHERT, B
PA (ASTA) ASTA MEDICA AG
CYC 17
PI EP 947200 A2 19991006 (199946)* DE 5p
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
ADT EP 947200 A2 Div ex EP 1994-101672 19940204, EP 1999-102340 19940204
FDT EP 947200 A2 Div ex EP 611572
PRAI DE 1993-4305225 19930219
AB EP 947200 A UPAB: 19991110
NOVELTY - Sterile freeze-dried **cetrorelix** acetate (a peptide

described in EP299402) is used in the treatment of female infertility.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following: (1) use of sterile freeze-dried **cetrorelix** acetate for protecting gonads against noxious agents that damage germ cells, e.g. radiation treatment and chemotherapy; (2) a composition comprising sterile freeze-dried **cetrorelix** acetate and optionally excipients for use in the treatment of female infertility; (3) a composition comprising sterile freeze-dried **cetrorelix** acetate and optionally excipients for protecting gonads against noxious agents that damage germ cells, e.g. radiation treatment and chemotherapy with cytostatic agents.

ACTIVITY - None given.

MECHANISM OF ACTION - Luteinizing hormone-releasing hormone (LHRH) antagonist.

USE - In an in-vitro fertilization procedure in which **cetrorelix** is administered to control the time of ovulation during an ovary stimulation treatment by preventing a pre-ovulation increase in luteinizing hormone (LH) levels, whereupon exogenous gonadotropin is administered to induce ovulation after follicle maturation.

Dwg.0/0

L7 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2001 ACS
AN 1999:708625 CAPLUS
DN 131:295922
TI Method for the treatment of fertility disorders using an LHRH antagonist to partially suppress endogenous gonadotropins during intrauterine insemination
IN **Engel, Jurgen**; Riethmuller-Winzen, Hilde; Reissmann, Thomas
PA Asta Medica Aktiengesellschaft, Germany
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9955357	A1	19991104	WO 1999-EP2133	19990329
	W: AU, BG, BR, BY, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9937028	A1	19991116	AU 1999-37028	19990329
	BR 9909802	A	20001226	BR 1999-9802	19990329

EP 1082129 A1 20010314 EP 1999-919152 19990329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
NO 2000005145 A 20001013 NO 2000-5145 20001013
PRAI US 1998-82743 P 19980423
WO 1999-EP2133 W 19990329
AB In the method of therapeutic management of infertility by intrauterine
insemination the improvement consisting of (a) the dose-dependent
suppression of endogenous gonadotropins, esp. LH, with a LH-RH Antagonist
allowing the maintenance of physiol. estrogen levels, (b) exogenous
stimulation of the ovarian follicle growth, (c) ovulation induction with
HCG, native LHRH, LHRH-Agonists or recombinant LH, (d) intrauterine
insemination by sperm injection. The LHRH Antagonists may be preferably
Cetrorelix or Antarelix. The stimulation is performed by
administration of HMG or recombinant FSH with or without recombinant LH or
with antiestrogens as for example Chlomiphene as well as with the
combination of antiestrogens as for example Chlomiphene with
gonadotropins.
RE.CNT 5
RE
(1) Asta Medica AG; EP 0611572 A 1994 CAPLUS
(2) Asta Medica AG; EP 0788799 A 1997 CAPLUS
(3) Bouchard, P; Ovul Ind Update '98, Proc World Conf, 2nd 1998, P115 CAPLUS
(4) Crowley, W; US 5130137 A 1992 CAPLUS
(5) Schering AG; DE 19604231 A 1997 CAPLUS

L7 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2001 ACS
AN 2000:739102 CAPLUS
DN 134:275789
TI Development of the LH-RH antagonist **Cetrorelix** for tumor therapy
AU Perrissoud, Daniel; Reissmann, Thomas; **Engel, Jurgen**
CS Corporate Research & Development ASTA Medica, Frankfurt, D-60314, Germany
SO Actual. Chim. Ther. (1999), 25, 243-249
CODEN: ACHTD9; ISSN: 0338-8999
PB Editions Scientifiques et Medicales Elsevier
DT Journal; General Review
LA English
AB A review with 10 refs. The availability of the LH-releasing hormone-antagonist **Cetrorelix** for clin. use opens up new therapeutic modalities of diseases dependent on sex hormones.
RE.CNT 10
RE
(1) Bajusz, S; Proc Natl Acad Sci 1988, V85, P1637 CAPLUS
(2) Behre, H; Exp and Clin Endocrinol 1994, V40, P241 CAPLUS
(6) Matsuo, H; Biochem Biophys Res Commun 1971, V43, P1334 CAPLUS
(7) Reissmann, T; Eur J Cancer 1996, V32A, P1574 CAPLUS
(8) Reissmann, T; Hum Reprod 1995, V10, P1974 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 15 OF 22 USPATFULL DUPLICATE 6
AN 1998:75185 USPATFULL
TI Long-acting injection suspensions and a process for their preparation
IN **Engel, Jurgen**, Alzenau, Germany, Federal Republic of
Klokkers-Bethke, Karin, Lenggries, Germany, Federal Republic of
Reissman, Thomas, Frankfurt, Germany, Federal Republic of
Hilgard, Peter, Frankfurt, Germany, Federal Republic of
PA Asta Medica Aktiengellschaft, Dresden, Germany, Federal Republic of
(non-U.S. corporation)
PI US 5773032 19980630
AI US 1996-661017 19960610 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Azpuru, Carlos A.
LREP Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 373
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Poorly soluble salts of LHRH analogues, for example **cetrorelix** embonate, display an intrinsic sustained release effect in the grain
size 5 .mu.m to 200 .mu.m.

L7 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2001 ACS
AN 1998:180776 CAPLUS
DN 128:226267
TI Means for treating prostate hypertrophy and prostate cancer with **Cetrorelix**, alone or in combination with other agents
IN **Engel, Jurgen**; Reissmann, Thomas; Riethmuller-Winzen, Hilde; Rawert, Jurgen
PA Asta Medica A.-G., Germany
SO PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9810781	A1	19980319	WO 1997-EP4740	19970901
W: AU, BR, CN, CZ, EE, HU, IL, IS, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6054432	A	20000425	US 1997-908198	19970807
AU 9746198	A1	19980402	AU 1997-46198	19970901
EP 925069	A1	19990630	EP 1997-944818	19970901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1230121	A	19990929	CN 1997-197904	19970901
BR 9713197	A	20000404	BR 1997-13197	19970901
JP 2001500500	T2	20010116	JP 1998-513204	19970901
CA 2215015	AA	19980312	CA 1997-2215015	19970910

	US 5998377	A	19991207	US 1998-57458	19980409
	US 6071882	A	20000606	US 1998-62704	19980420
	NO 9901192	A	19990428	NO 1999-1192	19990311
	US 6300313	B1	20011009	US 1999-401851	19990922
PRAI	US 1996-25990	P	19960912		
	US 1997-43228	P	19970410		
	US 1997-908198	A3	19970807		
	WO 1997-EP4740	W	19970901		
	US 1998-57458	A3	19980409		

AB A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs **Cetrorelix** alone or in combination with .alpha.-reductase inhibitors or .alpha.-receptor blocking agents. The regimen reduces the vol. of the prostate and avoids the side effects assocd. with testosterone levels being in a castration range. **Cetrorelix** is administered at dosages between 0.5 mg/day and 20 mg/wk or about 0.014 mg/kg body wt. per day to 0.30 mg/kg body wt. per wk or at levels of about 25 to 120 mg of **Cetrorelix** per mo or 0.376 mg/kg to 1.71 mg/kg per mo. **Cetrorelix** can be administered with .alpha.-reductase inhibitors or .alpha.-receptor blocking agents.

L7 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2001 ACS
AN 1999:538778 CAPLUS
DN 131:139954
TI LHRH antagonists in the treatment of fertility disorders
IN Bouchard, Philippe; Frydman, Rene; Diedrich, Klaus; **Engel, Jurgen**; Devroey, Paul
PA Asta Medica AG, Germany
SO Can. Pat. Appl., 15 pp.
CODEN: CPXXEB
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2200541	AA	19980722	CA 1997-2200541	19970320
PRAI	US 1997-786937		19970122		

AB A method of treating infertility disorders by administering an LH-RH antagonist, preferably **Cetrorelix**, in amts. to selectively suppress endogenous LH but not FSH secretion and inducing follicle growth by administration of exogenous gonadotropin. The selective suppression of LH allows FSH secretion to be at natural levels thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual s.c. dose in the range of 1 mg to 10 mg, preferably 2 mg - 6 mg. In multiple dosing posol., LH-RH antagonist can be administered s.c. in an amt. in the range of 0.1 to 0.5 mg of LH-RH antagonist/day. LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day

4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addn. rec. LH, native LH-RH or LH-RH agonist can be given to avoid hyperstimulation syndrome and native LH-RH or a LH-RH agonist can be administered to avoid luteal phase stimulation by neutralizing the neg. effects of HCG.

L7 ANSWER 18 OF 22 USPATFULL
AN 97:78416 USPATFULL
TI Products for administering an initial high dose of **Cetrorelix** and producing a combination package for use when treating diseases
IN **Engel, Jurgen**, Alzenau, Germany, Federal Republic of
Hilgard, Peter, Frankfurt, Germany, Federal Republic of
Reissmann, Thomas, Frankfurt, Germany, Federal Republic of
PA ASTA Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of
(non-U.S. corporation)
PI US 5663145 19970902
AI US 1994-354838 19941208 (8)
PRAI DE 1993-4342091 19931209
DT Utility
FS Granted
EXNAM Primary Examiner: Russel, Jeffrey E.
LREP Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP
CLMN Number of Claims: 25
ECL Exemplary Claim: 7
DRWN No Drawings
LN.CNT 227
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB For application during the treatment of benign and malign tumour diseases, the product according to the invention containing the initial dose of **Cetrorelix** acetate and one or more maintenance doses of **Cetrorelix** acetate, **Cetrorelix** embonate or a slow-release form of **Cetrorelix**, is used as a combination preparation for treatment to be administered at specific time intervals.

L7 ANSWER 19 OF 22 USPATFULL
AN 95:43015 USPATFULL
TI Compressed gas packages using polyoxyethylene glyceryl oleates
IN Hettche, Helmut, Dietzenbach, Germany, Federal Republic of
Engel, Jurgen, Alzenau, Germany, Federal Republic of
Muckenschnabel, Reinhard, Frankfurt, Germany, Federal Republic of
PA Asta Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of
(non-U.S. corporation)
PI US 5415853 19950516
AI US 1993-33789 19930317 (8)
PRAI DE 1992-42085055 19920317
DE 1992-42151880 19920508

DE 1992-42308763 19920916
DT Utility
FS Granted
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Benston, Jr.,
William E.
LREP Cushman Darby & Cushman
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 314
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Aerosol compressed gas packages containing a member of the group
consisting of polyoxyethylene-25-glyceryl trioleate, polyoxyethylene-30-glyceryl monooleate and polyoxyethylene-20-glyceryl
monooleate as suspension stabilizer and/or valve lubricant. These
materials are especially useful when the package contains TG 227 or TG
134a as the propellant.

L7 ANSWER 20 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
DUPLICATE
7
AN 1994-265229 [33] WPIDS
DNC C1994-121294
TI Freeze-dried peptide compsns. - prepd. by freeze drying soln. of peptide
in aq. acetic acid.
DC B04
IN ENGEL, J; REISSMANN, T; **SAUERBIER, D**; WICHERT, B; BURKHARD, W; JUERGEN, E
PA (ASTA) ASTA MEDICA AG
CYC 32
PI EP 611572 A2 19940824 (199433)* DE 5p
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
DE 4305225 A1 19940825 (199433) 5p
AU 9455235 A 19940825 (199436)
NO 9400564 A 19940822 (199436)
CA 2115943 A 19940820 (199439)
CZ 9400312 A3 19940914 (199439)
BR 9400617 A 19940927 (199440)
SK 9400195 A3 19940907 (199440)
FI 9400779 A 19940820 (199441)
JP 06271476 A 19940927 (199443) 5p
ZA 9401136 A 19941026 (199444) 12p
HU 67117 T 19950228 (199514)
EP 611572 A3 19950111 (199538)
AU 671881 B 19960912 (199644)
CN 1112019 A 19951122 (199737)
SG 46632 A1 19980220 (199822)
BR 1101004 A3 19980512 (199828)
CZ 284314 B6 19981014 (199847)
NZ 314707 A 19990225 (199914)
CZ 285768 B6 19991117 (200002)
EP 611572 B1 20000607 (200032) DE
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DE 59409389 G 20000713 (200037)
HU 218281 B 20000728 (200045)
RU 2145234 C1 20000210 (200048)
ES 2148247 T3 20001016 (200058)
TW 387812 A 20000421 (200061)

ADT EP 611572 A2 EP 1994-101672 19940204; DE 4305225 A1 DE 1993-4305225
19930219; AU 9455235 A AU 1994-55235 19940217; NO 9400564 A NO 1994-564
19940218; CA 2115943 A CA 1994-2115943 19940218; CZ 9400312 A3 CZ 1994-312
19940214; BR 9400617 A BR 1994-617 19940218; SK 9400195 A3 SK 1994-195
19940218; FI 9400779 A FI 1994-779 19940218; JP 06271476 A JP 1994-20532
19940217; ZA 9401136 A ZA 1994-1136 19940218; HU 67117 T HU 1994-481
19940218; EP 611572 A3 EP 1994-101672 19940204; AU 671881 B AU 1994-55235
19940217; CN 1112019 A CN 1994-101378 19940218; SG 46632 A1 SG 1996-6874
19940204; BR 1101004 A3 BR 1997-1101004 19970514; CZ 284314 B6 CZ 1994-312
19940214; NZ 314707 A Div ex NZ 1994-250906 19940217, NZ 1994-314707
19940217; CZ 285768 B6 CZ 1998-974 19940214; EP 611572 B1 EP 1994-101672
19940204, Related to EP 1999-102340 19940204; DE 59409389 G DE 1994-509389
19940204, EP 1994-101672 19940204; HU 218281 B HU 1994-481 19940218; RU
2145234 C1 RU 1994-5001 19940218; ES 2148247 T3 EP 1994-101672 19940204;
TW 387812 A TW 1994-100769 19940131

FDT AU 671881 B Previous Publ. AU 9455235; CZ 284314 B6 Previous Publ. CZ
9400312; NZ 314707 A Div ex NZ 250906; CZ 285768 B6 Previous Publ. CZ
9800974; EP 611572 B1 Related to EP 947200; DE 59409389 G Based on EP
611572; HU 218281 B Previous Publ. HU 67117; ES 2148247 T3 Based on EP
611572

PRAI DE 1993-4305225 19930219

AB EP 611572 A UPAB: 19991110

Freeze-dried compsns. comprising a peptide of 3-15 amino acid units and opt. one or more matrix materials are characterised in that 1 pt. wt. of the peptide is dissolved in 100-10,000 pts. wt. of acetic acid and then transferred to water and the resulting soln. is freeze dried.

USE/ADVANTAGE - The compsns. esp. contain **cetrorelix** (EP 299402), which is used in the treatment of female infertility (for controlling ovulation prior to isolating egg cells for in-vitro fertilisation) and for gonad protection in male patients (e.g. undergoing ratio- or chemotherapy). The aq. acetic acid soln. can be sterilised by

filtration without gelation or hydrolysis of the peptide.
Dwg.0/0

L7 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2001 ACS
AN 1996:316833 CAPLUS
DN 125:722
TI Persistent blockade of the pituitary gonadal axis in patients with
prostatic cancer by the LH-RH antagonist SB-75 (**Cetrorelix**)
AU Gonzalez-Barcena, D.; Vadillo-Buenfil, M.; Cortez-Morales, A.; Romero, M.
A.; Engel, J.; Comaru-Schally, A. M.; Schally, A. V.; **Reissman, Th.**
CS Hosp. Esp. C.M.R., IMSS, Mexico City, Mex.
SO Proc. Int. Cancer Congr., Free Pap. Posters, 16th (1994), Volume 3,
2201-2204. Editor(s): Rao, R. S. Publisher: Monduzzi Editore, Bologna,
Italy.
CODEN: 62UYAO
DT Conference
LA English
AB Our objective was to use the LH-RH analog SB-75, **Cetrorelix** to treat a group of patients with advanced prostrate carcinoma. The antagonists SB-75 was well tolerated. No local or systemic effects were
obsd. These results show that the chronic administration of the LH-RH
antagonists SB-75, **Cetrorelix** is an effective therapy for the management of advanced prostate cancer.

L7 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2001 ACS
AN 1995:228423 CAPLUS
DN 122:106501
TI Synthesis of [U-14C]Arg labeled decapeptide **cetrorelix**, a novel luteinizing hormone-releasing hormone antagonist
AU Locher, Mathias; Johnston, James; Muller, Thomas; Borbe, Harald O.;
Kutscher, Bernhard; **Engel, Jurgen**
CS ASTA Medica AG, Frankfurt, D-60001, Germany
SO J. Labelled Compd. Radiopharm. (1994), 34(11), 1091-8
CODEN: JLCRD4; ISSN: 0362-4803
DT Journal
LA English
AB The decapeptide **cetrorelix** is a novel LH-releasing hormone (LH-RH) antagonist. For nonclin. studies concerning absorption, distribution, metab. and excretion (ADME) in animals the [14C]-labeled
compd. is essential. Therefore, [U-14C]Arg **cetrorelix** acetate salt was synthesized by Amersham international, Buckinghamshire (England)
from precursor peptides provided by Degussa AG, Hanau-Wolfgang (Germany).
[U-14C]Arg labeled **cetrorelix** peptide base has a specific activity of 8.13 MBq/mg (220 .mu.Ci/mg) and a mol. wt. of 1442.6 g/mol at
this specific activity. The chem. and radiochem. purity (92.2% decapeptide content and 97.6%, resp.) detd. by HPLC is suitable for

nonclin. investigations.

```
=> e wolf ingrid/au

E1            1     WOLF INGETRAUT/AU
E2           15     WOLF INGO/AU
E3           40 --> WOLF INGRID/AU
E4            1     WOLF INGRID DE/AU
E5            3     WOLF INGRID H/AU
E6            1     WOLF IRENE/AU
E7            1     WOLF IRIS/AU
E8            3     WOLF IRMA/AU
E9            8     WOLF IRMELIN/AU
E10           4     WOLF IRVING/AU
E11          17     WOLF IRVING W/AU
E12           2     WOLF IRVING WILLIAM/AU

=> s e3-e5

L8           44 ("WOLF INGRID"/AU OR "WOLF INGRID DE"/AU OR "WOLF
INGRID H"/AU)

=> s l8 and cetrorelix

L9            0 L8 AND CETRORELIX

=> s l8 and lyophiliz?

L10           6 L8 AND LYOPHILIZ?

=> dup rem l10

PROCESSING COMPLETED FOR L10
L11           6 DUP REM L10 (0 DUPLICATES REMOVED)

=> d bib ab 1-6


L11  ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2001 ACS
AN   1992:46317  CAPLUS
DN   116:46317
TI   Preparation of a stable parenteral immunostimulant composition
containing
     splenopentin
IN   Wolf, Ingrid
PA   Berlin-Chemie A.-G., Germany
SO   Ger. (East), 3 pp.
     CODEN: GEXXA8
DT   Patent
LA   German
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   DD 292382          A5   19910801       DD 1990-338431   19900306
     DD 292382          B5   19940324
     EP 445581          A1   19910911       EP 1991-102431   19910220
     EP 445581          B1   19930505
         R:  AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE
```

	AT 88903	E	19930515	AT 1991-102431	19910220
	ES 2055469	T3	19940816	ES 1991-102431	19910220
	CA 2037531	AA	19910907	CA 1991-2037531	19910304
	JP 04211611	A2	19920803	JP 1991-38808	19910305
	JP 06092315	B4	19941116		
PRAI	DD 1990-338431		19900306		
	EP 1991-102431		19910220		

AB A stable, liq. or **lyophilized** immunostimulant prepn. for parenteral administration to humans contains splenopentin or its analogs combined with a hydroxybenzoic acid ester as stabilizer. Thus, 27 g diacetylsplenopentin-HCl was dissolved in 600 mL 0.02M H3PO4; the pH was adjusted to 8.0-9.0 with NaOH and then adjusted after 20 min to 7.5. Me hydroxybenzoate 1.5 g was dissolved in 300 mL water at 90-95.degree. and added to the above soln.; the pH was adjusted to 6.9-7.1 and the soln. was sterilized by filtration.

L11 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1989:463948 CAPLUS
DN 111:63948
TI Sustained-release pharmaceuticals containing peptide-sulfonated polystyrene complexes
IN Fechner, Klaus; Bienert, Michael; Klauschenz, Erhard; **Wolf, Ingrid** ; Mehlis, Burkhard; Loth, Fritz; Dautzenberg, Horst; Bergfeld, Jost
PA Akademie der Wissenschaften der DDR, Ger. Dem. Rep.
SO Ger. (East), 4 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DD 256605	A3	19880518	DD 1982-246469	19821223

AB Sustained-release pharmaceuticals contain complexes of biol. active peptides, polypeptides, or their derivs. or salts, with sulfonated polystyrene or its salts. Polystyrene (mol. wt. 200,000) was sulfonated and neutralized with NaOH to give a polymer with a degree of substitution of 1. A **lyophilizate** contg. 2.5 mg angiotensin and 25 mg sorbitol was dissolved in a soln. contg. 0.125% Na polystyrenesulfonate and isotonic NaCl to give an injection.

L11 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1981:127390 CAPLUS
DN 94:127390
TI **Lyophilized** LHRH preparations
IN **Wolf, Ingrid**; Schneider, Anita; Tschauschev, Peter
PA Ger. Dem. Rep.

SO Ger. (East), 5 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 141996	Z	19800604	DD 1979-211139	19790221

AB A stable LH-RH [9034-40-6] prepn. is made by buffering an aq. soln. of LH-RH to pH 3.5-6.5 and **lyophilizing**. For example, 4.5 g LH-RH, to 2 g citric acid [77-92-9] and 20 g mannitol (carrier) were dissolved in 900 mL H2O for injection, dild. to 1 L, and adjusted to pH 3.5-4.5 with 1N NaOH. The soln. was sterilized by filtration, divided into 1 mL aliquots, and **lyophilized**.

L11 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1980:169260 CAPLUS
DN 92:169260
TI Lyophilicized hypotensive preparation for parenteral application
IN **Wolf, Ingrid**; Klehr, Gabriele
PA Ger. Dem. Rep.
SO Ger. (East), 6 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 138406	Z	19791031	DD 1978-207389	19780821
DD 138406	B1	19860507		

AB A pharmaceutical prepn. of di-Na pentacyanonitrosylferrate (I) [14402-89-2], stable for several y and suitable for parenteral application, with I contg. 5-50 mg-% K, was prepd. by adding an acidic or neutral amino acid or a Na salt of a weak acid and(or) mannitol and **lyophilizing** the soln. Thus, 50 g I contg. 5 mg-% K was dissolved with 20 g mannitol [69-65-8] in 1 L freshly-distd. H2O and the soln. sterile-filtered, aseptically filled into 1 mL brown glass ampuls, and **lyophilized**.

L11 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1975:484842 CAPLUS
DN 83:84842
TI **Lyophilized** gastrin preparations
IN **Wolf, Ingrid**
PA E. Ger.
SO Ger. (East), 6 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 109512	Z	19741112	DD 1974-176286	19740131

AB A parenteral applicable gastrin [9002-76-0] prepn. which is stable at room temp. is prepd. by adding trometamol [77-86-1] to a gastrin soln. and **lyophilization**. A soln. of the **lyophilized** gastrin is made immediately before application.

L11 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1974:137186 CAPLUS
DN 80:137186
TI Parenterally applicable angiotensin preparation with depot action
IN Matthias, Dietrich; Baumann, Hannelore; Engler, Eberhard; **Wolf, Ingrid**
SO Ger. (East), 2 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 98610	Z	19730712	DD 1972-163087	19720515

AB A title prepn. is made by dissolving 2.5 mg **lyophilized** angiotensin (I) in 1.1-1.5 ml aq. 10-50% soln. of poly(vinylpyrrolidinone)(mol. wt. 25,000-35,000), or as tablets, by mixing I with 2 g lactose or NaCl + 2% talc to yield 2.5-50 mg implants contg. 1.0-5.5 mg I. Both prepns. caused a rise in blood pressure of rats.

=> d his

(FILE 'HOME' ENTERED AT 15:53:06 ON 07 NOV 2001)

FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS, AGRICOLA, LIFESCI, BIOTECHDS, JICST-EPLUS' ENTERED AT 15:53:14 ON 07 NOV 2001

		E ENGEL JURGEN/AU
L1	222	S E3
		E WICHERT BURKHARD/AU
L2	12	S E3-E4
		E SAUERBIER DIETER/AU
L3	42	S E1-E3
		E REISSMAN THOMAS/AU
L4	5	S E1-E4
L5	261	S L1-L4
L6	29	S L5 AND CETRORELIX
L7	22	DUP REM L6 (7 DUPLICATES REMOVED)
		E WOLF INGRID/AU
L8	44	S E3-E5
L9	0	S L8 AND CETRORELIX
L10	6	S L8 AND LYOPHILIZ?
L11	6	DUP REM L10 (0 DUPLICATES REMOVED)

=> s l8 and lyophili?

L12 6 L8 AND LYOPHILI?

=> d bib 1-6

L12 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1992:46317 CAPLUS
DN 116:46317
TI Preparation of a stable parenteral immunostimulant composition containing
splenopentin
IN **Wolf, Ingrid**
PA Berlin-Chemie A.-G., Germany
SO Ger. (East), 3 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 292382	A5	19910801	DD 1990-338431	19900306
	DD 292382	B5	19940324		
	EP 445581	A1	19910911	EP 1991-102431	19910220
	EP 445581	B1	19930505		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	AT 88903	E	19930515	AT 1991-102431	19910220
	ES 2055469	T3	19940816	ES 1991-102431	19910220
	CA 2037531	AA	19910907	CA 1991-2037531	19910304
	JP 04211611	A2	19920803	JP 1991-38808	19910305
	JP 06092315	B4	19941116		
PRAI	DD 1990-338431		19900306		
	EP 1991-102431		19910220		

L12 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1989:463948 CAPLUS
DN 111:63948
TI Sustained-release pharmaceuticals containing peptide-sulfonated polystyrene complexes
IN Fechner, Klaus; Bienert, Michael; Klauschenz, Erhard; **Wolf, Ingrid**
; Mehlis, Burkhard; Loth, Fritz; Dautzenberg, Horst; Bergfeld, Jost
PA Akademie der Wissenschaften der DDR, Ger. Dem. Rep.
SO Ger. (East), 4 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 256605	A3	19880518	DD 1982-246469	19821223

L12 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1981:127390 CAPLUS
DN 94:127390
TI **Lyophilized** LHRH preparations

IN **Wolf, Ingrid**; Schneider, Anita; Tschauschev, Peter
PA Ger. Dem. Rep.
SO Ger. (East), 5 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 141996	Z	19800604	DD 1979-211139	19790221

L12 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1980:169260 CAPLUS
DN 92:169260
TI **Lyophilicized** hypotensive preparation for parenteral application
IN **Wolf, Ingrid**; Klehr, Gabriele
PA Ger. Dem. Rep.
SO Ger. (East), 6 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 138406	Z	19791031	DD 1978-207389	19780821
	DD 138406	B1	19860507		

L12 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1975:484842 CAPLUS
DN 83:84842
TI **Lyophilized** gastrin preparations
IN **Wolf, Ingrid**
PA E. Ger.
SO Ger. (East), 6 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 109512	Z	19741112	DD 1974-176286	19740131

L12 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1974:137186 CAPLUS
DN 80:137186
TI Parenterally applicable angiotensin preparation with depot action
IN Matthias, Dietrich; Baumann, Hannelore; Engler, Eberhard; **Wolf, Ingrid**
SO Ger. (East), 2 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 98610	Z	19730712	DD 1972-163087	19720515

=> d clm 3

'CLM' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers; SCAN must be entered on the same line as the DISPLAY, e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, IPC, and NCL

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT) containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and its structure diagram
FHITSTR ----- First HIT RN, its text modification, its CA index name, and its structure diagram
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, KWIC, and OCC) may be used with DISPLAY ACC to view a

specified Accession Number.
ENTER DISPLAY FORMAT (BIB):.

L12 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1981:127390 CAPLUS
DN 94:127390
TI **Lyophilized** LHRH preparations
IN **Wolf, Ingrid**; Schneider, Anita; Tschauschev, Peter
PA Ger. Dem. Rep.
SO Ger. (East), 5 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 141996	Z	19800604	DD 1979-211139	19790221

=> e schneider anita/au

E1	8		SCHNEIDER ANGELA/AU
E2	10		SCHNEIDER ANGELIKA/AU
E3	1	-->	SCHNEIDER ANITA/AU
E4	3		SCHNEIDER ANITA M H/AU
E5	11		SCHNEIDER ANJA/AU
E6	8		SCHNEIDER ANKE/AU
E7	1		SCHNEIDER ANN/AU
E8	3		SCHNEIDER ANN T/AU
E9	2		SCHNEIDER ANNA/AU
E10	2		SCHNEIDER ANNA M/AU
E11	14		SCHNEIDER ANNE/AU
E12	5		SCHNEIDER ANNE MARIE/AU

=> s e3-e4

L13 4 ("SCHNEIDER ANITA"/AU OR "SCHNEIDER ANITA M H"/AU)

=> d bib ab 1-4

L13 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2001 ACS
AN 1981:127390 CAPLUS
DN 94:127390
TI Lyophilized LHRH preparations
IN Wolf, Ingrid; **Schneider, Anita**; Tschauschev, Peter
PA Ger. Dem. Rep.
SO Ger. (East), 5 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 141996	Z	19800604	DD 1979-211139	19790221

AB A stable LH-RH [9034-40-6] prepn. is made by buffering an aq. soln. of
LH-RH to pH 3.5-6.5 and lyophilizing. For example, 4.5 g LH-RH, to 2 g

citric acid [77-92-9] and 20 g mannitol (carrier) were dissolved in 900
mL H2O for injection, dild. to 1 L, and adjusted to pH 3.5-4.5 with 1N
NaOH. The soln. was sterilized by filtration, divided into 1 mL aliquots,
and lyophilized.

L13 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2001 ACS
AN 1975:507670 CAPLUS
DN 83:107670
TI Standardization of potassium permanganate solutions by titration with
sodium oxalate in the presence of perchloric acid and manganese(II)
sulfate
AU Ohlweiler, Otto A.; **Schneider, Anita M. H.**
CS Inst. Quim., Univ. Fed. Rio Grande Sul, Porto Alegre, Brazil
SO An. Assoc. Bras. Quim. (1972), 28(1-2), 23-9
CODEN: AABQAL
DT Journal
LA Portuguese
AB Substituting HClO4 for H2SO4 in the standardization of 0.1N KMnO4 by
direct titrn. of Na2C2O4 in the presence of MnSO4 permits the titrn. at
any temp. between 25.degree. and 80.degree.. The HClO4 concn. is
maintained >2N. The KMnO4 soln. can be added at rates .ltoreq.12 ml/min.

L13 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2001 ACS
AN 1972:121112 CAPLUS
DN 76:121112
TI Standardization of potassium permanganate by titration of sodium oxalate
in presence of perchloric acid and manganese(II) sulfate
AU Ohlweiler, O. A.; **Schneider, Anita M. H.**
CS Inst. Quim., Univ. Fed., Porto Alegre, Brazil
SO Anal. Chim. Acta (1972), 58(2), 477-80
CODEN: ACACAM
DT Journal
LA English
AB KMnO4 (0.1 N) was standardized with 0.24 or 0.26 parts/103 std. deviation
by titrating 0.08-0.09N Na2C2O4, in the presence of HClO4 and MnSO4
catalyst, with the KMnO4 soln. at 25.degree. or 60.degree., resp.

L13 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2001 ACS
AN 1970:50566 CAPLUS
DN 72:50566
TI Colorimetric determination of cobalt with phthalocyanine
AU Meditsch, Jorge de Oliveira; **Schneider, Anita M. H.**
CS Univ. Rio Grande do Sul, Rio Grande do Sul, Brazil
SO Rev. Quim. Ind. (Rio de Janeiro) (1969), 38(446), 16-18
CODEN: RQIRAI
DT Journal
LA Portuguese
AB Heat 200 mg of flux (phthalic anhydride 14.8, urea 6, and boric acid 0.1 g

) with the Co++ soln. at 160-5.degree.C for 5 min and ext. the Co complex
form ed with acetone. After making up to vol. measure the absorbance at
622 m.mu. Co++ can be detd. in the 2.5-20 ppm range. The av. relative
error is 5%. Fe++ and Cu++ interfere, .ltoreq.100 ppm of Ni++ can be
tolerated, while Ca++, Ba++, Sr++, Mg++, Zn++, Cd++, Hg++, and Mn++ do not
interfere.

=> e tschauschev peter/au

```
E1            1     TSCHAUSCHE S J/AU
E2           14     TSCHAUSCHEV P/AU
E3            4 --> TSCHAUSCHEV PETER/AU
E4            1     TSCHAUSHEV G/AU
E5            1     TSCHAUSHEV P/AU
E6            4     TSCHAUT R J/AU
E7            3     TSCHAUTSCHEV P/AU
E8            3     TSCHAWDAROVA R/AU
E9            2     TSCHAWDAROWA M/AU
E10           2     TSCHAWOW A/AU
E11           1     TSCHAWOW ANTOANETA/AU
E12           4     TSCHAWRAKOW G/AU
```

=> s e2-e5

L14 20 ("TSCHAUSCHEV P"/AU OR "TSCHAUSCHEV PETER"/AU OR "TSCHAUSHEV G"/AU OR "TSCHAUSHEV P"/AU)

=> s l14 and lyophili?

L15 1 L14 AND LYOPHILI?

=> d bib ab

L15 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS
AN 1981:127390 CAPLUS
DN 94:127390
TI **Lyophilized** LHRH preparations
IN Wolf, Ingrid; Schneider, Anita; **Tschauschev, Peter**
PA Ger. Dem. Rep.
SO Ger. (East), 5 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 141996	Z	19800604	DD 1979-211139	19790221

AB A stable LH-RH [9034-40-6] prepn. is made by buffering an aq. soln. of
LH-RH to pH 3.5-6.5 and **lyophilizing**. For example, 4.5 g LH-RH,
to 2 g citric acid [77-92-9] and 20 g mannitol (carrier) were dissolved

in 900 mL H2O for injection, dild. to 1 L, and adjusted to pH 3.5-4.5 with
1N NaOH. The soln. was sterilized by filtration, divided into 1 mL
aliquots, and **lyophilized**.

=> s cetrorelix and lyophili?

L16 22 CETRORELIX AND LYOPHILI?

=> dup rem l16

PROCESSING COMPLETED FOR L16
L17 19 DUP REM L16 (3 DUPLICATES REMOVED)

=> d bib ab 1-19

L17 ANSWER 1 OF 19 USPATFULL DUPLICATE 1
AN 2001:14464 USPATFULL
TI Pharmaceutical formulations for sustained drug delivery
IN Gefter, Malcolm L., Lincoln, MA, United States
Barker, Nicholas, Southborough, MA, United States
Musso, Gary, Hopkinton, MA, United States
Molineaux, Christopher J., Brookline, MA, United States
PA Praecis Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
corporation)
PI US 6180608 B1 20010130
AI US 1997-988851 19971211 (8)
RLI Continuation-in-part of Ser. No. US 1996-762747, filed on 11 Dec 1996,
now patented, Pat. No. US 5968895
DT Utility
FS Granted
EXNAM Primary Examiner: Cintins, Marianne M.; Assistant Examiner: Delacroix-Muirheid, C.
LREP Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Laccotripe, Maria C.
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 1333
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Sustained delivery formulations comprising a water-insoluble complex of
a peptidic compound (e.g., a peptide, polypeptide, protein, peptidomimetic or the like) and a carrier macromolecule are disclosed.
The formulations of the invention allow for loading of high concentrations of peptidic compound in a small volume and for delivery
of a pharmaceutically active peptidic compound for prolonged periods,
e.g., one month, after administration of the complex. The complexes of
the invention can be milled or crushed to a fine powder. In powdered

form, the complexes form stable aqueous suspensions and dispersions, suitable for injection. In a preferred embodiment, the peptidic compound of the complex is an LHRH analogue, preferably an LHRH antagonist, and the carrier macromolecule is an anionic polymer, preferably carboxymethylcellulose. Methods of making the complexes of the invention, and methods of using LHRH-analogue-containing complexes to treat conditions treatable with an LHRH analogue, are also disclosed.

L17 ANSWER 2 OF 19 USPATFULL
AN 2001:144937 USPATFULL
TI Solid matrix therapeutic compositions
IN Unger, Evan C., Tucson, AZ, United States
PA ImaRx Therapeutics, Inc. (U.S. corporation)
PI US 2001018072 A1 20010830
AI US 2001-828762 A1 20010409 (9)
RLI Division of Ser. No. US 1998-75477, filed on 11 May 1998, PENDING
PRAI US 1997-46379 19970513 (60)
DT Utility
FS APPLICATION
LREP Mackiewicz & Norris LLP, One Liberty Place - 46th Floor, Philadelphia, PA, 19103
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a solid porous matrix comprising a surfactant in combination with a bioactive agent. The solid porous matrix may be prepared by combining a surfactant and a therapeutic, together with a solvent, to form an emulsion containing random aggregates of the surfactant and the therapeutic, and processing the emulsion by controlled drying, or controlled agitation and controlled drying to form the solid porous matrix.

L17 ANSWER 3 OF 19 USPATFULL
AN 2001:90106 USPATFULL
TI Methods for detecting lesions in dense breast tissue using LHRH antagonists
IN Garnick, Marc B., Brookline, MA, United States
PA Praecis Pharmaceuticals Incorporated (U.S. corporation)
PI US 2001002249 A1 20010531
AI US 2001-764626 A1 20010118 (9)
RLI Continuation of Ser. No. US 1998-67327, filed on 27 Apr 1998, GRANTED, Pat. No. US 6217844
DT Utility
FS APPLICATION

LREP LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 687
AB Improved methods for detecting lesions in dense breast tissue are disclosed. The methods of the invention generally feature administration to a subject of an LHRH antagonist in an amount and for a period of time sufficient to reduce the density of breast tissue prior to generating an image of the breast tissue, for example by mammography, to detect a lesion in the breast tissue. Packaged formulations for reducing breast density in a subject prior to generating an image of the subject's breast tissue, comprising an LHRH antagonist packaged with instructions for using the LHRH antagonist to reduce breast density in a subject prior to imaging the breast tissue, are also disclosed.

L17 ANSWER 4 OF 19 USPATFULL
AN 2001:121065 USPATFULL
TI Attaching agents to tissue with transglutaminase and a transglutaminase substrate
IN Green, Howard, 82 Williston St., Brookline, MA, United States 02146
Corey, George D., 65 Harding St., Newton, MA, United States 02165
Compton, Bruce J., 30 Cottage St., Lexington, MA, United States 02173
Dijan, Philippe, 170, rue de la Convention, 75015 Paris, France
PI US 6267957 B1 20010731
AI US 1999-234358 19990120 (9)
PRAI US 1998-71908 19980120 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Naff, David M.
LREP Wolf, Greenfield & Sacks, P.C.
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1730
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods, products and kits are provided for attaching agents to tissue with a linking molecule in the presence of transglutaminase. The linking molecule and/or agent is a substrate of transglutaminase. The agent can be a nonprotein or an enzyme such as cholinesterase or phosphodiesterase. The transglutaminase may be exogenously added or be endogenous in tissue. In specific embodiments, the linking molecule

contains at least two contiguous linked glutamines or at least three contiguous linked lysines. A conjugate of the agent and the linking molecule may be applied to tissue, and in the presence of transglutaminase covalently bonded to the tissue via the linking molecule. A complementary linking molecule rich in lysines may be first attached to the tissue in the presence of transglutaminase, and then covalently bonded to a glutamine-containing linking molecule of the conjugate in the presence of transglutaminase. In another embodiment, a linking molecule containing multiple glutamines is covalently bonded to tissue in the presence of transglutaminase, and an agent containing multiple lysines is covalently bonded to the linking molecule in the presence of transglutaminase. Alternatively, the linking molecule contains multiple lysines and the agent contains multiple glutamines. Two tissues can be sealed together by holding the tissues in contact with each other in the presence of transglutaminase.

L17 ANSWER 5 OF 19 USPATFULL
AN 2001:108015 USPATFULL
TI Process for the one-stage resalting and purification of oligopeptides
IN Gunther, Kurt, Staatsangehorigkeit, Germany, Federal Republic of
Kunz, Franz-Rudolf, Staatsangehorigkeit, Germany, Federal Republic of
Drauz, Karlheinz, Staatsangehorigkeit, Germany, Federal Republic of
Muller, Thomas, Staatsangehorigkeit, Germany, Federal Republic of
PA Degussa-Huls Aktiengesellschaft, Germany, Federal Republic of (non-U.S. corporation)
PI US 6258933 B1 20010710
AI US 1999-276709 19990326 (9)
PRAI DE 1998-19813849 19980327
DT Utility
FS GRANTED
EXNAM Primary Examiner: Low, Christopher S. F.
LREP Pillsbury Madison & Sutro LLP
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 507
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a process for the one-stage resalting and purification of oligopeptides. Oligopeptides are often not formed

directly as acetates when synthesised. Acetate salts of oligopeptides are however desirable as bulk-active material for medical and formulation reasons. Processes known from the prior art have hitherto involved two separate steps or pyridine-containing solvents. The resalting and purification can be combined in one step and the use of pyridine as solvent can be avoided, if the oligopeptide in the form of its chloride salt is purified with an acetate-containing solvent by liquid chromatography methods.

L17 ANSWER 6 OF 19 USPATFULL
AN 2001:55422 USPATFULL
TI Methods for detecting lesions in dense breast tissue using LHRH antagonists
IN Garnick, Marc B., Brookline, MA, United States
PA Praecis Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6217844 B1 20010417
AI US 1998-67327 19980427 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Jones, Dameron
LREP Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Laccotripe, Maria C.
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 768
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Improved methods for detecting lesions in dense breast tissue are disclosed. The methods of the invention generally feature administration to a subject of an LHRH antagonist in an amount and for a period of time sufficient to reduce the density of breast tissue prior to generating an image of the breast tissue, for example by mammography, to detect a lesion in the breast tissue. Packaged formulations for reducing breast density in a subject prior to generating an image of the subject's breast tissue, comprising an LHRH antagonist packaged with instructions for using the LHRH antagonist to reduce breast density in a subject prior to imaging the breast tissue, are also disclosed.

L17 ANSWER 7 OF 19 USPATFULL
AN 2001:52022 USPATFULL
TI GnRH antagonists being modified in positions 5 and 6
IN Semple, Graeme, Gothenburg, Sweden

Jiang, Guangcheng, San Diego, CA, United States
PA Ferring BV, Hoofddorp, Netherlands (non-U.S. corporation)
PI US 6214798 B1 20010410
WO 9846634 19981022
AI US 2000-402698 20000103 (9)
WO 1998-US7438 19980413
20000103 PCT 371 date
20000103 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1997-837042, filed on 11 Apr 1997,
now patented, Pat. No. US 5925730
DT Utility
FS Granted
EXNAM Primary Examiner: Jones, Dwayne C.; Assistant Examiner: Delacroix-Muirheid, C.
LREP Fitch, Even, Tabin & Flannery
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1463
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Peptides are provided which have improved duration of GnRH antagonistic
properties. These antagonists may be used to regulate fertility and to
treat steroid-dependent tumors and for other short-term and long-term
treatment indications. These antagonists have a derivative of aminoPhe
or its equivalent in the 5- or the 5- and 6-positions. This derivative
is modified so as to contain a carbamoyl group or heterocycle, including
a urea moiety, in its side chain. Decapeptides having the formula:

Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(L-hydroorotyl)-D-4Amf(Q.sub.2)-Leu-Lys(isopropyl)-Pro-Xaa.sub.10,

wherein Q.sub.2 is Cbm or MeCbm and Xaa.sub.10 is D-Ala-ol or Ala-ol are
particularly effective and continue to exhibit very substantial
suppression of LH secretion at 96 hours following injection.

L17 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2001 ACS
AN 2001:764638 CAPLUS
TI Low-temperature micronization of a peptide drug in fluid propellant: case
study **cetrorelix**
AU Lizio, Rosario; Damm, Michael; Sarlikiotis, Antonio W.; Bauer, Horst H.;
Lehr, Claus-Michael
CS Dep. Biopharmaceutics and Pharmaceutical Technol., Saarland Univ.,
Saarbrucken, 66123, Germany
SO AAPS PharmSciTech (2001), 2(3), No pp. given
CODEN: AAPHFZ; ISSN: 1522-1059
URL: http://www.aapspharmaceutica.com/scientificjournals/volume2issue3/049

/manuscript.pdf
PB American Association of Pharmaceutical Scientists
DT Journal; (online computer file)
LA English
AB Aim of this study was to elaborate an efficient method for the micronization of the decapeptide **cetrorelix** (a GnRH-antagonist), in order to obtain a microsuspension as basis for other pharmaceutical prepns., such as e.g. inhalation aerosols. A modified pearl-mill coupled with a cryostat was used for the micronization of **cetrorelix** in fluid propellant and operated under different conditions. The obtained **cetrorelix** suspensions were analyzed for particle size distribution, purity of **cetrorelix**, and for metal contamination through abrasion from parts of the mill. The method allowed an effective micronization of **cetrorelix**. The mean particle size of the initial **cetrorelix lyophilizate** bulk were was reduced from 52.5 .mu.m (Vol. Mean Diam., VMD) down to 14.9, 6.1 and 3.1 .mu.m, resp., resp. The HPLC anal. of all **cetrorelix** suspensions after micronization did not show signs of decompn. as compared to the initial product. The elementary anal. of the suspensions performed by inductively coupled plasma mass spectrometry revealed a negligible amt. of contaminants in the suspension (Zr = max. 0.6 ppm; Fe, Cr, Ni, Ba, below limit of quantification, i.e. < 0.14 ppm). The only appreciable contaminant, Aluminum (Al = 1.1 ppm), was derived from the mech. capping of aluminum canisters prior to anal. The Zr detn. in the suspension of 0.6 ppm, is still considered to be negligible as compared to the legally tolerated limit of air contamination. By low-temp. micronization in fluid propellant, fine drug suspensions of **cetrorelix** for pMDIs can be directly manufd. in one-step procedure without destruction of the peptide structure and without appreciable product contamination.

L17 ANSWER 9 OF 19 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 2
AN 2000:477618 BIOSIS
DN PREV200000477618
TI Process for the preparation of immobilized and activity-stabilized complexes of LHRH antagonists.
AU Engel, Jurgen (1); Deger, Wolfgang; Reissmann, Thomas; Losse, Gunter; Naumann, Wolfgang; Murgas, Sandra
CS (1) Alzenau Germany
ASSIGNEE: Asta Medica Aktiengesellschaft, Dresden, Germany
PI US 6054555 April 25, 2000
SO Official Gazette of the United States Patent and Trademark Office Patents, (Apr. 25, 2000) Vol. 1233, No. 4, pp. No pagination. e-file. ISSN: 0098-1133.

DT Patent
LA English
AB In this invention, a release-delaying system is to be developed for LHRH antagonists, in particular for **cetrorelix**, which allows the active compound to be released in a controlled manner over several weeks by complexation with suitable biophilic carriers. The acidic polyamino acids polyglutamic acid and polyaspartic acid were selected for complexation with **cetrorelix**. The **cetrorelix** polyamino acid complexes are prepared from aqueous solutions by combination of the solutions and precipitation of the complexes, which are subsequently centrifuged off and dried over P2 O5 in vacuo. If complexes having a defined composition are to be obtained, **lyophilization** proves to be a suitable method. The **cetrorelix**-carboxylic acid complexes were also prepared from the aqueous solutions. In the random liberation system, the acidic polyamino acids poly-Glu and poly-Asp showed good release-delaying properties as a function of the hydrophobicity and the molecular mass of the polyamino acid. In animal experiments, it was possible to confirm the activity of the **cetrorelix**-polyamino acid complexes as a depot system in principle. It is thus possible by complexation of **cetrorelix** with polyamino acids to achieve testosterone suppression in male rats over 600 hours. The release of active compound here can be controlled by the nature and the molecular mass of the polymers.

L17 ANSWER 10 OF 19 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 3
AN 2000:355483 BIOSIS
DN PREV200000355483
TI Immobilized and activity-stabilized complexes of LHRH antagonists and processes for their preparation.
AU Engel, Jurgen (1); Deger, Wolfgang; Reissmann, Thomas; Losse, Gunter; Naumann, Wolfgang; Murgas, Sandr
CS (1) Alzenau Germany
ASSIGNEE: Asta Medica Aktiengesellschaft, Dresden, Germany
PI US 6022860 February 08, 2000
SO Official Gazette of the United States Patent and Trademark Office Patents, (Feb. 8, 2000) Vol. 1231, No. 2, pp. No pagination. e-file. ISSN: 0098-1133.
DT Patent
LA English
AB In this invention, a release-delaying system is to be developed for LHRH antagonists, in particular for **cetrorelix**, which allows the active compound to be released in a controlled manner over several weeks

by complexation with suitable biophilic carriers. The acidic polyamino acids polyglutamic acid and polyaspartic acid were selected for complexation with **cetrorelix**. The **cetrorelix** polyamino acid complexes are prepared from aqueous solutions by combination of the solutions and precipitation of the complexes, which are subsequently centrifuged off and dried over P2 O5 in vacuo. If complexes having a defined composition are to be obtained, **lyophilization** proves to be a suitable method. The **cetrorelix**-carboxylic acid complexes were also prepared from the aqueous solutions. In the random liberation system, the acidic polyamino acids poly-Glu and poly-Asp showed good release-delaying properties as a function of the hydrophobicity and the molecular mass of the polyamino acid. In animal experiments, it was possible to confirm the activity of the **cetrorelix**-polyamino acid complexes as a depot system in principle. It is thus possible by complexation of **cetrorelix** with polyamino acids to achieve testosterone suppression in male rats over 600 hours. The release of active compound here can be controlled by the nature and the molecular mass of the polymers.

L17 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2001 ACS
AN 2000:573692 CAPLUS
DN 133:182987
TI Sustained release salts of pharmaceutically active peptides and their production
IN Bauer, Horst; Deger, Wolfgang; Sarlikiotis, Werner; Damm, Michael
PA Asta Medica A.-G., Germany
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000047234	A1	20000817	WO 2000-EP697	20000129

W: AU, BG, BR, BY, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRAI US 1999-119076 P 19990208
AB Substained delivery pharmaceutical compns. comprise a water insol. salt of a pharmaceutically active ionic peptide and a counterionic carrier

macromol. The peptide may be an LHRH antagonist such as **cetrorelix** and the macromol. may be an anionic polysaccharide such as CM-cellulose. The salt is prepd. using ion exchangers to sep. remove the counterions from the peptide and the carrier macromol. thereby forming free peptide/macromol. ions. These free peptide and macromol. ions are then combined to form the water insol. peptide-macromol. salt. A **lyophilizate** of **cetrorelix**-CM-cellulose salt was prepd.

RE.CNT 6
RE
(1) Asta Medica Ag; WO 9842381 A 1998 CAPLUS
(2) Kamei, S; WO 9832423 A 1998 CAPLUS
(3) Klokkers-Bethke, K; US 5773032 A 1998 CAPLUS
(4) Molineaux, C; WO 9825642 A 1998 CAPLUS
(5) Nestor, J; US 4581169 A 1986 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 12 OF 19 USPATFULL
AN 1999:128511 USPATFULL
TI Pharmaceutical formulations for sustained drug delivery
IN Gefter, Malcolm L., Lincoln, MA, United States
Barker, Nicholas, Southborough, MA, United States
Musso, Gary, Hopkinton, MA, United States
Molineaux, Christopher J., Brookline, MA, United States
PA Praecis Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5968895 19991019
AI US 1996-762747 19961211 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner: Delacroix-Muirheid, C.
LREP Lahive & Cockfield, LLP, Mandragouras, Amy E., DeConti, Giulio A.
CLMN Number of Claims: 32
ECL Exemplary Claim: 10
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 775
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Sustained delivery formulations comprising a water-insoluble complex of a peptide and a carrier macromolecule are disclosed. The formulations of the invention allow for loading of high concentrations of peptide in a small volume and for delivery of a pharmaceutically active peptide for prolonged periods, e.g., one month, after administration of the complex. The complexes of the invention can be milled or crushed to a fine powder. In powdered form, the complexes form stable aqueous suspensions and dispersions, suitable for injection. In a preferred embodiment, the

peptide of the complex is an LHRH analogue, preferably an LHRH antagonist, and the carrier macromolecule is an anionic polymer, preferably carboxymethylcellulose. Methods of making the complexes of the invention, and methods of using LHRH-analogue-containing complexes to treat conditions treatable with an LHRH analogue, are also disclosed.

L17 ANSWER 13 OF 19 USPATFULL
AN 1999:99641 USPATFULL
TI LH-RH antagonists having improved action
IN Kutscher, Bernhard, Maintal, Germany, Federal Republic of
Bernd, Michael, Frankfurt, Germany, Federal Republic of
Beckers, Thomas, Frankfurt, Germany, Federal Republic of
Klenner, Thomas, Ingelheim, Germany, Federal Republic of
Emig, Peter-Paul, Bruchkobel, Germany, Federal Republic of
Charpentier, Patricia-Marie, Maintal, Germany, Federal Republic of
PA ASTA Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of
(non-U.S. corporation)
PI US 5942493 19990824
AI US 1998-87274 19980528 (9)
RLI Continuation-in-part of Ser. No. WO 1996-DE2171, filed on 14 Nov 1996
PRAI DE 1995-19544212 19951128
DT Utility
FS Granted
EXNAM Primary Examiner: Davenport, Avis M.
LREP Pillsbury Madison & Sutro LLP
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1219
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB New LH-RH antagonists are disclosed, in particular peptidomimetics and peptides modified in a side chain, their salts with pharmaceutically acceptable acids and a process for preparing these LH-RH antagonists and their salts. The disclosed peptides represent analogues of the luteinising hormone releasing hormone (LH-RH). The disclosed compounds have a high antagonistic power and are free of undesirable side effects, in particular edematogenic effects.

L17 ANSWER 14 OF 19 USPATFULL
AN 1999:81921 USPATFULL
TI GnRH antagonists
IN Semple, Graeme, Hampshire, United Kingdom
Jiang, Guangcheng, San Diego, CA, United States
PA Ferring BV, Hoofddorp, Netherlands (non-U.S. corporation)
PI US 5925730 19990720
AI US 1997-837042 19970411 (8)
DT Utility

FS Granted
EXNAM Primary Examiner: Hill, Jr., Robert J.; Assistant Examiner: Delacroix-Muirheid, C.
LREP Fitch, Even, Tabin & Flannery
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1458
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Peptides are provided which have improved duration of GnRH antagonistic properties. These antagonists may be used to regulate fertility and to treat steroid-dependent tumors and for other short-term and long-term treatment indications. These antagonists have a derivative of aminoPhe or its equivalent in the 5- and/or 6-positions. This derivative contains a carbamoyl group or a heterocycle including a urea in its side chain. Particularly effective decapeptides, which continue to exhibit very substantial suppression of LH secretion at 96 hours following injection, have the formulae: Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(hydroorotyl)-D-4Aph(acetyl)-Leu-Lys(isopropyl)-Pro-D-Ala-NH.sub.2, and

Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(hydroorotyl)-D-4Amf(Q.sub.2)-Leu-Lys(isopropyl)-Pro-D-Ala-NH.sub.2, wherein Q.sub.2 is Cbm or MeCbm.

L17 ANSWER 15 OF 19 USPATFULL
AN 1998:124554 USPATFULL
TI GnRH antagonist decapeptides
IN Jiang, Guangcheng, San Diego, CA, United States
Semple, Graeme, Hamphire, United Kingdom
PA Ferring BV, Hoofddorp, Netherlands (non-U.S. corporation)
PI US 5821230 19981013
AI US 1997-837041 19970411 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Wang, Cecilia F.
LREP Fitch, Even, Tabin & Flannery
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1630
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Peptides are provided which have improved duration of GnRH antagonistic properties and/or which can be synthesized more economically. These antagonists may be used in the same manner as the compounds of which they are analogs to regulate fertility and to treat steroid-dependent

tumors and for other short-term and long-term treatment indications. One particularly effective peptide, a decapeptide analog of the GnRH antagonist Acyline, has the formula: Ac-D-2Nal-D-4Cpa-D-Dpr(methylcarbamoyl)-Ser-4Aph(acetyl)-D-4Aph(acetyl)-Leu-Lys(isopropyl)-Pro-D-Ala-NH.sub.2. It continues to exhibit very substantial suppression of LH secretion at 96 hours following injection. Other economically attractive and pharmacologically effective analogs have the formulas: Ac-D-2Nal-D-4Cpa-Xaa.sub.3-Ser-4Aph(acetyl)-D-4Aph(acetyl)-Leu-Lys(isopropyl)-Pro-D-Ala-NH.sub.2 ; and Ac-D-2Nal-D-4Cpa-Xaa.sub.3-Ser-4Aph(hydroorotyl)-D-4Aph(acetyl)-Leu-Lys(isopropyl)-Pro-D-Ala-NH.sub.2, wherein Xaa.sub.3 is D-Gln or Gln.

L17 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2001 ACS
AN 1998:672495 CAPLUS
DN 129:293891
TI Immobilized activity-stabilized LHRH antagonist complexes and their production
IN Engel, Juergen; Deger, Wolfgang; Reissmann, Thomas; Losse, Guenter; Naumann, Wolfgang; Murgas, Sandra
PA Asta Medica Aktiengesellschaft, Germany
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9842381	A1	19981001	WO 1998-EP1398	19980311
	W: AU, BR, CA, CN, CZ, HU, IL, JP, MX, NO, NZ, PL, RU, SK, TR, UA				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	DE 19712718	A1	19981001	DE 1997-19712718	19970326
	DE 19712718	C2	19990923		
	AU 9869207	A1	19981020	AU 1998-69207	19980311
	BR 9807887	A	20000222	BR 1998-7887	19980311
	EP 981377	A1	20000301	EP 1998-914877	19980311
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001520662	T2	20011030	JP 1998-544811	19980311
	US 6022860	A	20000208	US 1998-48244	19980326
	NO 9904665	A	19990924	NO 1999-4665	19990924
	US 6054555	A	20000425	US 1999-422990	19991022
PRAI	DE 1997-19712718	A	19970326		
	WO 1998-EP1398	W	19980311		
	US 1998-48244	A3	19980326		

AB LHRH antagonists, esp. **cetrorelix**, are complexed with suitable biophilic carriers to enable sustained, targeted release of the active substance over a period of several weeks. The acidic polyamino acids, polyaspartic and polyglutamic acids, are selected for complexation with **cetrorelix**. The **cetrorelix**/polyamino acid complexes are produced from aq. solns. by combining the solns. and pptg. the complexes which are subsequently centrifuged off and vacuum dried over P2O5, preferably by **lyophilization**. These acidic polyamino acids display good sustained-release properties in a static liberation system depending on the hydrophobicity and molar mass of the polyamino acids.
Animal testing demonstrated the efficacy of the **cetrorelix** /polyamino acid complexes as a depot system. By complexation of **cetrorelix** with polyamino acids, testosterone suppression can be achieved in male rats over a period of 600 h. Active substance release can thus be controlled according to polymer type and molar mass.

L17 ANSWER 17 OF 19 USPATFULL
AN 97:78416 USPATFULL
TI Products for administering an initial high dose of **Cetrorelix** and producing a combination package for use when treating diseases
IN Engel, Jurgen, Alzenau, Germany, Federal Republic of
Hilgard, Peter, Frankfurt, Germany, Federal Republic of
Reissmann, Thomas, Frankfurt, Germany, Federal Republic of
PA ASTA Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of
(non-U.S. corporation)
PI US 5663145 19970902
AI US 1994-354838 19941208 (8)
PRAI DE 1993-4342091 19931209
DT Utility
FS Granted
EXNAM Primary Examiner: Russel, Jeffrey E.
LREP Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP
CLMN Number of Claims: 25
ECL Exemplary Claim: 7
DRWN No Drawings
LN.CNT 227
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB For application during the treatment of benign and malign tumour diseases, the product according to the invention containing the initial dose of **Cetrorelix** acetate and one or more maintenance doses of **Cetrorelix** acetate, **Cetrorelix** embonate or a slow-release form of **Cetrorelix**, is used as a combination preparation for treatment to be administered at specific time intervals.

L17 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1995:677500 CAPLUS
DN 123:65874
TI Products for the application of high initial doses of **cetrorelix** and preparation of a combined package for use in treating diseases
IN Engel, Juergen; Hilgard, Peter; Reissmann, Thomas
PA Asta Medica A.-G., Germany
SO Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 657170	A1	19950614	EP 1994-118466	19941124
	EP 657170	B1	20000315		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 190495	E	20000415	AT 1994-118466	19941124
	ES 2145803	T3	20000716	ES 1994-118466	19941124
	CA 2137595	AA	19950610	CA 1994-2137595	19941208
	US 5663145	A	19970902	US 1994-354838	19941208
	JP 07194670	A2	19950801	JP 1994-306475	19941209
PRAI	DE 1993-4342091	A	19931209		

AB A pharmaceutical product, esp. suitable for treatment of hormone-dependent tumors, comprises a package of containers, of which .gtoreq.1 containers contain an initial dose of drug and .gtoreq.1 addnl. containers each contain a maintenance dose. The maintenance doses may be in delayed-release form. Thus, a 1-mo supply of **cetrorelix** comprised .gtoreq.1 container contg. an initial dose (1-60 mg) **lyophilized cetrorelix** acetate and .ltoreq.30 addnl. containers contg. a maintenance dose (0.1-10 mg) **lyophilized cetrorelix** acetate.

L17 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2001 ACS
AN 1994:587330 CAPLUS
DN 121:187330
TI Preparation of a **cetrorelix lyophilized** composition
IN Engel, Juergen; Sauerbier, Dieter; Wichert, Burkhard; Reissmann, Thomas
PA Asta Medica AG, Germany
SO Eur. Pat. Appl., 5 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 611572	A2	19940824	EP 1994-101672	19940204
	EP 611572	A3	19950111		
	EP 611572	B1	20000607		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	DE 4305225	A1	19940825	DE 1993-4305225	19930219
	TW 387812	B	20000421	TW 1994-83100769	19940131
	EP 947200	A2	19991006	EP 1999-102340	19940204

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE

	AT 193653	E	20000615	AT 1994-101672	19940204
	ES 2148247	T3	20001016	ES 1994-101672	19940204
	CZ 284314	B6	19981014	CZ 1994-312	19940214
	CZ 285768	B6	19991117	CZ 1998-974	19940214
	AU 9455235	A1	19940825	AU 1994-55235	19940217
	AU 671881	B2	19960912		
	JP 06271476	A2	19940927	JP 1994-20532	19940217
	PL 177177	B1	19991029	PL 1994-302266	19940217
	CA 2115943	AA	19940820	CA 1994-2115943	19940218
	FI 9400779	A	19940820	FI 1994-779	19940218
	NO 9400564	A	19940822	NO 1994-564	19940218
	ZA 9401136	A	19940829	ZA 1994-1136	19940218
	BR 9400617	A	19940927	BR 1994-617	19940218
	HU 67117	A2	19950228	HU 1994-481	19940218
	HU 218281	B	20000728		
	CN 1112019	A	19951122	CN 1994-101378	19940218
	RU 2145234	C1	20000210	RU 1994-5001	19940218
PRAI	DE 1993-4305225	A	19930219		
	EP 1994-101672	A3	19940204		

AB A **lyophilizate** of a peptide with 3-15 amino acid residues (e.g. **cetrorelix**) and .gtoreq.1 optional matrix materials (e.g. mannitol) is prepd. by dissolving in 100-10,000 wt. parts AcOH, dilg. with water, and **lyophilizing** the resulting soln. The **lyophilizate** is useful for prepn. of a medication for treatment of female infertility and protection of the gonads from the follicular hyperstimulation seen with other infertility treatments.